Dare Bioscience Registers Resale of 8.9M Warrant Shares From $6M Offering
DARE is trading near its 52-week low of $0.74 (9.5% above the low).
Summary
Dare Bioscience filed an S-1 to register the resale of 8.9 million shares underlying warrants from its August 14, 2026 private placement. The filing names the selling stockholders and discloses up to $12.4 million in potential cash proceeds from warrant exercises.
Key Events · Financing and Capital Events · DARE
-
Resale Registration for 8.9M Warrant Shares
S-1 registers resale of 8,934,345 shares underlying Series A/B warrants and placement agent warrants issued in the August 14, 2026 private placement.
-
Selling Stockholders Identified
Lind Global Fund III LP holds 12.68% beneficial ownership, Armistice Capital 10.02%, and L1 Capital 10.02% as of August 20, 2026.
-
Potential $12.4M Cash Inflow
Company may receive up to approximately $12.4 million if all common warrants and placement agent warrants are exercised for cash.
-
Placement Agent Warrant Terms
Placement agent warrants have a $2.1235 exercise price, 155% of the $1.37 public offering price, exercisable until August 14, 2031.
Analysis · DARE · Life Sciences
This S-1 registers the resale of 8,934,345 shares underlying warrants issued in the August 14, 2026 private placement. The filing reveals the selling stockholders — Lind Global Fund III LP (12.68% beneficial ownership), Armistice Capital (10.02%), and L1 Capital (10.02%) — and discloses that the company could receive up to $12.4 million if all warrants are exercised for cash. The placement agent warrants carry a $2.1235 strike price, 155% above the $1.37 offering price. The Nasdaq hearing occurred August 25, 2026, with a decision expected within 30 days. Against a backdrop of going-concern doubt and a delisting notice, this registration makes the warrant overhang tradable and quantifies the potential cash inflow that could help the company regain Nasdaq compliance.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DARE was trading at $0.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.9M. The 52-week trading range was $0.74 to $3.78. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.